HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cancer drug trial seeks to control advanced tumors
Disease control Recruiting nowThis early-stage study aims to find safe doses and gather initial evidence on whether a new drug called BGB-43395 can help control advanced cancers. The trial will enroll about 300 people with hormone-positive, HER2-negative breast cancer that has spread, as well as other solid t…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug combo aims to outsmart tough breast cancer
Disease control Recruiting nowThis study is testing if adding a newer drug called elacestrant to the standard treatment olaparib works better for controlling advanced breast cancer in people with specific BRCA gene mutations. About 176 participants will be randomly assigned to receive either the two-drug comb…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First human trial launches for promising new cancer pill targeting multiple tumors
Disease control Recruiting nowThis is an early-stage study testing a new oral drug called BG-68501 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for Tough-to-Treat breast cancer: experimental combo enters human trials
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new drug, VS-6766, when combined with two existing breast cancer drugs (abemaciclib and fulvestrant). It is for people with advanced HR+/HER2- breast cancer that has worsened despite prior standard treatments. The goal is to…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New drug trial targets Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing a new drug called EP0062, both alone and combined with standard treatments, for women with a specific type of advanced breast cancer that has come back after prior therapy. The main goals are to find the safest and most effective dose and to see how well the…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New drug combo tested to control Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing whether adding an experimental drug called alisertib to standard hormone therapy can better control advanced breast cancer that has stopped responding to previous hormone treatments. It will enroll about 150 adults whose cancer has returned or spread and aim…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
Period power: could your cycle change your cancer treatment?
Knowledge-focused Recruiting nowThis study aims to understand how a woman's menstrual cycle affects breast cancer tumor growth and whether this information, along with genetic tests, helps doctors make better treatment decisions. Researchers will follow 504 women with early-stage, hormone-positive breast cancer…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC